CJC-1295 No DAC Research: Tendon Considerations

CJC-1295 without DAC is a growth hormone–releasing hormone (GHRH) analog studied for its short-duration stimulation of endogenous growth hormone release. Interest in it for tendon and connective-tissue research is indirect: it derives from the well-documented role of the GH/IGF-1 axis in collagen turnover, not from tendon-endpoint trials of this specific molecule. For a business buyer, that distinction is the whole story — it dictates how the compound can be described in a catalog, what documentation should accompany every vial, and why purity specifications matter more here than in almost any other category.

This is research-use-only material. Nothing below is dosing, preparation, or administration guidance, and nothing here should be read as a claim about outcomes in people.

What the missing DAC actually changes

CJC-1295 is built on the 1-29 fragment of GHRH with amino acid substitutions that slow enzymatic breakdown. The DAC — Drug Affinity Complex — is an added moiety designed to bind serum albumin, which markedly extends how long the molecule persists in circulation in published pharmacokinetic work. Strip that moiety out and you are left with the tetrasubstituted GHRH analog frequently catalogued as CJC-1295 no DAC, or mod GRF 1-29.

The practical consequence in a research setting is duration. The DAC-bearing version produces a prolonged elevation of the signal; the no-DAC version produces a comparatively brief one. Investigators studying the growth hormone axis often prefer the shorter-acting form precisely because it allows discrete secretory events to be observed and measured against baseline, rather than flattening the picture with sustained exposure. Studies of GHRH analogs also indicate that the pituitary response is shaped by somatostatin feedback, model age, and metabolic state — variables that are easier to isolate when the stimulus is short.

For a wholesale buyer, none of that is a selling point to repeat to customers. It is background you need so that your catalog copy stays accurate: the two versions are not interchangeable, they are not the same SKU, and customers who order one when they meant the other will generate returns and complaints.

Why connective tissue enters the conversation at all

The link runs through IGF-1. Research indicates that growth hormone drives hepatic and local IGF-1 expression, and that IGF-1 signaling is involved in tenocyte proliferation and type I collagen synthesis. Studies measuring collagen fractional synthesis rates in tendon and surrounding peritendinous tissue report responsiveness to this axis. That is the entire mechanistic bridge between a GHRH analog and tendon research interest.

It is a real bridge, but it is a long one. Tendon is hypovascular and metabolically slow; matrix turnover is measured in long timeframes, and mechanical loading appears in the literature as a dominant variable in its own right. Investigators working in this area typically use tenocyte culture systems, animal tendon injury models, or biomarker approaches rather than expecting a systemic secretagogue to produce a localized structural effect. Research in this space also consistently separates collagen quantity from collagen organization and tensile quality — an increase in synthesis markers is not the same finding as improved tissue architecture.

So when someone asks about CJC-1295 no DAC in a tendon context, the honest framing is that the compound is a tool for manipulating an upstream signal that connective-tissue researchers care about. It is not a tendon compound.

Where the evidence is thinner than the marketing

Three gaps are worth knowing before your catalog says anything at all:

There is no direct tendon-outcome literature on this analog to lean on. Much of what circulates online extrapolates from GH or IGF-1 research and attributes it to the secretagogue. That extrapolation is not a citation, and a business that repeats it inherits the risk.

Response variability is substantial across models. Secretagogue studies report that the magnitude of GH release depends on the model, feedback state, and timing of measurement. Any supplier or influencer presenting a single clean number as the expected result is describing a study you should ask to see.

Compounds with more direct connective-tissue literature exist, and they are still research-use-only. Peptides such as BPC-157 and TB-500 appear far more often in tendon and ligament injury models than any GHRH analog does. That does not make them approved for anything — it means the research context is different, and your catalog should reflect that difference rather than blurring categories together.

Qualitatively: this is a compound where careful, hedged language is not just a compliance chore, it is the accurate description.

Purity variables that decide whether tendon data replicates

Connective-tissue research is unusually sensitive to material quality. Tenocyte cultures respond to endotoxin. Long-duration animal studies amplify the effect of impurities. And because tendon endpoints move slowly, a contaminated or misidentified batch can waste months before anyone notices. If your customers are running this kind of work, the documentation you ship with the vial is the product.

The pattern to watch for is a supplier that supplies a certificate for a batch rather than your batch. A representative COA tells you what the manufacturer can produce on a good day. A lot-matched COA tells you what is in the box.

Questions to resolve before you add it to your catalog

This section is informational and is not legal advice. Regulatory treatment of research-use-only materials varies, and the answers below belong to your attorney and, where applicable, your state board — not to a supplier's blog post.

The questions worth putting in front of counsel generally include: How should research-use-only materials be labeled and described in your own storefront and marketing? What restrictions apply to who you may sell to, and how do you document that a buyer qualifies? What recordkeeping obligations attach to purchase and resale in your jurisdiction? Does your business insurance respond to this product category, and has your carrier been told in writing? If you hold a professional license, what does your board say about a separate commercial entity distributing research materials?

Treat any supplier that answers these confidently on your behalf as a warning sign. A supplier can tell you what is in the vial and can hand you the documentation to prove it. What you are permitted to do next is a question for your own advisors, and a reputable wholesale program will say exactly that.

One more sourcing note that is commercial rather than legal: pricing opacity is common in this industry. Programs that hide tier pricing behind a sales call, charge for certificates of analysis separately, or reference "third-party tested" without publishing anything retrievable are asking you to buy on trust. Margins and volume economics vary widely by category and order size, so the only way to compare two programs honestly is to see both sets of numbers and both sets of lab results before you commit.

What Real Peptides does differently

Real Peptides publishes what most of the industry keeps behind a login. Every compound in the catalog, including CJC-1295 No DAC, is manufactured to a 99%+ HPLC purity specification and runs through a 7-panel batch test. The resulting certificates of analysis are publicly verifiable — a prospective partner can pull up the lab results and read them before placing a first order, without asking a sales rep for permission and without paying for the document.

Fulfillment is US-based, with orders shipping in 5–7 days. Wholesale onboarding is a 3-step application: submit business details, get reviewed for program fit, and receive tier pricing. There is no hidden pricing structure to negotiate your way into and no separate charge for the documentation your customers will ask you for.

What Real Peptides does not do is equally deliberate. No dosing guidance, no preparation instructions, and no protocol support are provided for any compound, because these are research-use-only materials. When a customer asks a concentration question, the only educational framework offered is the underlying milligram-per-milliliter relationship — the arithmetic of concentration itself, never an amount, a volume, or a procedure. A supplier that hands out protocols alongside research chemicals is telling you something about its compliance posture, and it is not flattering.

If you are evaluating this category for your catalog, the useful test is simple: ask both suppliers for a lot-matched COA on a compound you would actually stock, and see which one can produce it in under a minute.

For operators who have done that homework and want transparent tier pricing on verified material, the Wholesale Partner Program application is the next step — three steps, business verification, and pricing that does not depend on how hard you negotiate.

Buyers researching this category typically compare the short-acting CJC-1295 No DAC 10mg against other secretagogue-adjacent options such as Ipamorelin 10mg and Tesamorelin 10mg, and against compounds with more direct connective-tissue literature like BPC-157 10mg and TB-500 10mg; the broader Growth Factor & Tissue Signaling Research and Performance & Recovery Research collections show how those categories are organized across the catalog.